Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

Now Viewing

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Related Videos

Related Content

Advertisement

September 3rd 2025

FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C

Hayden E. Klein

September 3rd 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

September 3rd 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

September 3rd 2025

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

September 3rd 2025

Community Health Centers Expand Lp(a) Screening to Reduce Cardiovascular Risk

Hayden E. Klein

September 3rd 2025

Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

Brooke McCormick

Related Content

Advertisement

September 3rd 2025

FDA Expands Evolocumab Label for Adults With Increased MACE Risk From Uncontrolled LDL-C

Hayden E. Klein

September 3rd 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

September 3rd 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

September 3rd 2025

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

September 3rd 2025

Community Health Centers Expand Lp(a) Screening to Reduce Cardiovascular Risk

Hayden E. Klein

September 3rd 2025

Pediatric Hypertension Increasing Among Children, Adolescents Worldwide

Brooke McCormick